| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1037: Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 25 mg/ml concentrate for solution for infusion |
| Reference number | 4520 |
| Indication | As monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum‑based chemotherapy |
| Company | Merck Sharp & Dohme (UK) Limited |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/02/25 |
| NICE guidance | TA1037: Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer |